InvestSMART

Syntara Limited (ASX:SNT)

ALERT: Price-sensitive ASX Announcement for SNT
Current share price for SNT : $0.025 0 (0%)+
Announcement
Release
10 Jun 2026 3:07PM
Price at Release
$0.025
Full Release
download
Summary
Syntara Limited, a clinical-stage drug development company, announced the successful completion of its Share Purchase Plan (SPP), raising approximately $0.84 million through applications. The shares were offered at a discount to the last closing price, resulting in the issuance of over 31 million new shares. This funding, combined with a previous placement, brings the total raised to approximately $8.84 million. The proceeds will support various initiatives, including key clinical trial readouts, preparation for a Phase 2b study on myelofibrosis, patent suite strengthening, and covering offer costs. Syntara's lead drug candidate, amsulostat, targeted for myelofibrosis, has received Fast Track and Orphan Drug Designations from the FDA.
Key Points
  • Successful completion of Share Purchase Plan (SPP) by Syntara Limited.
  • SPP received approximately $0.84 million in applications.
  • Shares offered at A$0.027, a 15.6% discount to the last closing price before announcement.
  • Total of 31,235,279 new fully paid ordinary shares issued under the SPP.
  • Proceeds from SPP and previous placement amount to approximately $8.84 million.
  • Funds to be used for trial readouts, Phase 2b MF study preparation, patent suite strengthening, and offer costs.
  • Lead candidate amsulostat for myelofibrosis has completed Phase 2a trial.
  • AMSULOSTAT granted Fast Track and Orphan Drug Designations by FDA.
  • Syntara listed on Australian Securities Exchange under code SNT.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.